RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Relief Therapeutics reported positive safety findings for ZYESAMI (RLF-100) in the NIH-sponsored ACTIV-3b study. The Independent Data Safety Monitoring Board reviewed data from 231 patients and confirmed no new safety concerns, recommending continued patient enrollment. The company emphasizes its commitment to addressing unmet medical needs with innovative therapies while also strengthening its pipeline through collaborations and acquisitions. The progress of RLF-100, particularly in treating respiratory issues related to COVID-19, remains a focus for Relief.

Relief Therapeutics announces that its subsidiary, APR Applied Pharma Research, published findings in the Journal of Wound Care indicating that Nexodyn(R) Acid-Oxidizing Solution (AOS) exhibits superior wound healing compared to standard care. Conducted by experts in Austria, the study involved 50 patients and demonstrated significant improvements including a healing rate of 32% with Nexodyn(R) versus 8% with standard treatment. The study confirmed Nexodyn(R)'s safety, tolerability, and its ability to reduce wound pH, promoting faster healing.

Relief Therapeutics Holding SA (OTCQB: RLFTF) announced that its U.S. partner, NRx Pharmaceuticals, has reported positive top-line data for ZYESAMI™ (RLF-100™/aviptadil) in highly comorbid COVID-19 patients. The treatment showed a threefold increase in one-year survival rates, consistent with prior phase 2b/3 trial results indicating enhanced 60-day survival rates. Relief focuses on clinical-stage therapies, with RLF-100™ targeting respiratory deficiencies due to COVID-19. The company also diversifies its pipeline through collaborations and recent acquisitions.

Relief Therapeutics Holding SA reported its half-year results for 2021, highlighting a focus on developing therapeutic products for severe diseases. The company has transformed into a multi-product, revenue-generating entity, primarily driven by the acquisition of APR Applied Pharma Research. Key developments include the filing of an NDA for ACER-001 and ongoing trials for RLF-100 (aviptadil), aimed at treating COVID-19 and other serious conditions. Despite a net loss of CHF 14.7 million, Relief maintains a strong cash position of CHF 40 million, positioning itself for strategic growth.

Relief Therapeutics announced positive findings regarding its PKU GOLIKE(R) product, developed by its subsidiary APR Applied Pharma Research. Data published in Nutrients suggests that the controlled release amino acid mix can reduce catabolic events in patients with phenylketonuria (PKU), enhancing amino acid utilization and improving quality of life. The product is recognized for its prolonged-release formulation which mimics natural protein absorption. Future clinical assessments are planned to support these findings, aiming for PKU GOLIKE(R) to become a prescription product in the U.S.

Relief Therapeutics announced on September 13, 2021, that it received scientific advice from the MHRA regarding its lead drug candidate, RLF-100 (aviptadil), aimed at treating respiratory deficiency in severe COVID-19 cases. The MHRA suggested a conditional marketing approval (CMA) pathway, allowing for early access to treatments. Relief also discussed the regulatory path with the EMA and indicated ongoing dialogue with the MHRA for necessary data from a Phase 2b/3 study conducted by NeuroRx. However, NeuroRx has yet to provide all required data, presenting potential risks.

Relief Therapeutics has announced the launch of PKU GOLIKE(R) KRUNCH, a chewable tablet designed for the dietary management of phenylketonuria (PKU), a rare genetic disorder affecting around 350,000 individuals globally. This new product aims to enhance patient adherence to therapy, providing a convenient 'on-the-go' option. The launch, taking place in Germany and Italy, leverages the Physiomimic Technology(TM) to offer a prolonged-release formulation that masks the product's unpleasant taste. Future expansion plans include additional markets across Europe.

Relief Therapeutics Holding AG (RLFTF) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CFO Jack Weinstein will present a company overview, available on-demand starting September 13 at 7:00 AM ET on Relief's website. The presentation will be archived for 90 days. Relief focuses on clinical-stage programs, particularly RLF-100^TM for COVID-19 respiratory deficiency. Additionally, Relief has collaborated with Acer Therapeutics on ACER-001 for treating Urea Cycle Disorders.

Relief Therapeutics (OTCQB: RLFTF) has responded to assertions made by NRx Pharmaceuticals in their September 3, 2021, Registration Statement. Relief disputes claims regarding the collaboration surrounding RLF-100 (aviptadil), specifically challenging accusations of misleading financial obligations and instability in the drug's formulation. Relief insists it has met all financial responsibilities and has requested transparency from NRx on clinical trial data and invoices. Relief also believes it can enforce its rights under the Collaboration Agreement if disputes remain unresolved.